DOCSLIB.ORG

Online Appendix

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Online Appendix The More We Die, The More We Sell? A Simple Test of the Home-Market Effect Online Appendix Arnaud Costinot Dave Donaldson MIT, CEPR, and NBER MIT, CEPR, and NBER Margaret Kyle Heidi Williams Mines ParisTech and CEPR MIT and NBER December 28, 2018 1 Contents A Theoretical Appendix3 A.1 Multinational Enterprises (Section III.1)..........................3 A.2 Log-Linearization (Section III.2)...............................3 A.3 Beyond Perfect Competition (Section III.3).........................6 A.3.1 Monopolistic Competition..............................6 A.3.2 Variable Markups...................................7 A.3.3 Endogenous Innovation...............................8 A.3.4 Price Regulations...................................9 A.4 Bilateral Sales (Section VI.1)................................. 12 B Empirical Appendix 12 B.1 Rich versus Poor Countries................................. 12 B.2 Additional Empirical Results................................ 13 B.3 Benchmarking IMS MIDAS data.............................. 13 B.3.1 Benchmarking to the OECD HealthStat Data................... 13 B.3.2 Benchmarking to the MEPS Data.......................... 14 B.4 ATC to GBD Mapping.................................... 15 2 A Theoretical Appendix A.1 Multinational Enterprises (Section III.1) In this appendix, we illustrate how to incorporate multinational production into our basic envi- ronment. Following Ramondo and Rodríguez-Clare(2013), suppose that each firm headquartered in country i that sells drugs targeting disease n in country j 6= i can choose the country l in which its production takes place. If l = i, then the firm exports, if l = j, it engages in horizontal FDI, and if l 6= i, j, it engages in platform FDI. Like in Ramondo and Rodríguez-Clare(2013), we assume that firm-level production functions exhibit constant returns to scale, but we further allow for external economies of scale at the level of the headquarter country for each disease. Formally, at each production site l, we assume that the marginal cost of a firm from country i serving country j is constant and given by n n n n cij(l) = c(si /hi )kij(l), (A.1) n n where c(si /hi ) captures the extent of economies of scale, which depends on the total supply of n n n tech n ship drugs targeting disease n in country i, and kij(l) = cil(til ) (tlj ) captures the costs of inputs n for firms from country i producing drugs targeting disease n in country l, cil, the potential frictions n tech associated with replicating Home’s technology in country l, (til ) , as well as the trade costs n ship associated with shipping goods from country l to country j, (tlj ) . The previous specification allows, for instance, firms from country i to combine imported inputs from their country with local factors of production in country l. In equilibrium, all firms from country i will serve country n j from the location l that minimizes their unit costs cij(l) across all l and charge an equilibrium price, n n pij = minfcij(l)g. (A.2) l n n n n n Now set pi ≡ c(si /hi ) and tij = minlfkij(l)g. By construction, equation (4) holds with s(·) = c−1(·), whereas equation (5) derives from equations (A.1) and (A.2). A.2 Log-Linearization (Section III.2) In this appendix, we derive equation (7) by log-linearizing our model around a symmetric equi- n n n n librium with qj = 1 for all j and n; hi = 1 for all i and n; tii = 1 for all i and n and tij = t for all n and i 6= j. We let D, d, and x denote aggregate drug consumption, the per disease expenditure on domestic drugs, and the per disease expenditure on drugs from any other country, respectively, in the symmetric equilibrium. In turn, we let l = d/(d + (I − 1)x) denote the share of expenditure on domestic drugs, with I the total number of countries. In the symmetric equilibrium, l is also equal to the share of revenue on the domestic market. Finally, without loss of generality, we nor- n malize all drug prices, pi , to one in the symmetric equilibrium and we let Pdis and Pagg denote the 3 n common values of Pj and Pj across all disease-destination pairs and destinations, respectively. Up to a first-order approximation, for all n and i 6= j, equations (1), (2), and (5) imply n n x n n n ln xij = ln x + ln qj − e (ln pi − ln Pj + ln Pdis + ln tij − ln t) (A.3) D n n n − e (ln Pj − ln Pdis − ln Pj + ln Pagg) + ln Dj − ln D + ln pi + ln tij − ln t. x ≡ −( ( ) ) D ≡ −( ( ) ) with e d ln d z /d ln z z=t/Pdis and e d ln D z /d ln z z=Pdis/Pagg . Taking logs and dif- ferentiating equation (3) around the symmetric equilibrium, we also get 8 ( − x) ¶ ln Pn < 1−l 1 e , if i 6= j, j = I−1 1−led−(1−l)ex n l(1−ed) ¶ ln pij : = 1−led−(1−l)ex , if i j, d ≡ −( ( ) ) with e d ln d z /d ln z z=1/Pdis . Up to a first-order approximation, we therefore have l(1 − ed) 1 − l (1 − ex) ln Pn = ln P + ln pn + (ln pn + ln tn − ln t). j dis d x j − d x ∑ l lj 1 − le − (1 − l)e I 1 1 − le − (1 − l)e l6=j Combining the previous expression with equation (A.3), we obtain 1 − l (1 − ex)(ex − eD) l(1 − ed)(ex − eD) ln xn =k + ln qn + (1 − ex + ) ln pn + ln pn (A.4) ij j j I − 1 1 − led − (1 − l)ex i 1 − led − (1 − l)ex j 1 − l (1 − ex)(ex − eD) 1 − l (1 − ex)(ex − eD) + (ln pn + ln tn) + (1 − ex + ) ln tn, − − d − ( − ) x ∑ l lj − − d − ( − ) x ij I 1 1 le 1 l e l6=i,j I 1 1 le 1 l e with x x (1 − l)(1 − e ) x D D k ≡ ln x + (e − (e − e ) − 1) ln t + e (ln P − ln Pagg) + ln D − ln D. j 1 − led − (1 − l)ex j j For i = j, the same logic implies l(1 − ed)(ed − eD) ln xn =k˜ + ln qn + (1 − ed + ) ln pn (A.5) ii i i 1 − led − (1 − l)ex i 1 − l (1 − ex)(ed − eD) + (ln pn + ln tn), − d x ∑ l li I 1 1 − le − (1 − l)e l6=i with x (1 − l)(1 − e ) d D D k˜ ≡ ln d − (e − e ) ln t + e (ln P − ln Pagg) + ln D − ln D. i 1 − led − (1 − l)ex i i Next, let us compute producer prices around a symmetric equilibrium. Up to a first-order approx- 4 imation, for all i and n, equations (4), (5), and (6) imply (1 − l) (1 + es) ln pn + ln hn = l(ln xn − ln d) + (ln xn − ln x), i i ii − ∑ ij I 1 j6=i s with e ≡ (d ln s(z)/d ln z)z=1. Together with equations (A.4) and (A.5), this implies (ew − eD) (1 − l) (es + ew) ln pn − ln pn = l ln qn + ln qn + xn, i − ∑ l i − ∑ j i I 1 l6=i I 1 j6=i with l2(1 − ed)(ed − eD) (1 − ex)(ex − eD) (1 − l)2 ew ≡ led + (1 − l)ex − − , 1 − led − (1 − l)ex 1 − led − (1 − l)ex I − 1 (1 − l) xn ≡ l(k˜ − ln d) + (k − ln x) − ln hn i i − ∑ j i I 1 j6=i 1 − l (1 − ex)(ed − eD) (1 − l)2 (1 − ex)(ex − eD) + l ln tn + ln tn − − d − ( − ) x ∑ li ( − )2 − d − ( − ) x ∑ ∑ lj I 1 1 le 1 l e l6=i I 1 1 le 1 l e j6=i l6=i,j (1 − l) 1 − l (1 − ex)(ex − eD) + (1 − ex + ) ln tn. − − d x ∑ ij I 1 I 1 1 − le − (1 − l)e j6=i The solution to the previous system is given by (l − 1−l ) xn ln pn = I−1 ln qn + i + zn, (A.6) i s w ew−eD i s w ew−eD e + e + I−1 e + e + I−1 with w D ( 1−l + ew−eD ) n + 1 (e −e ) n I−1 (es+eD)(I−1) ∑j ln qj (es+eD) I−1 ∑l xl zn ≡ . s w ew−eD e + e + I−1 Combining equations (A.4) and (A.6), we obtain, for any n and i 6= j, n n n n n ln xij = dij + d + bM ln qj + bX ln qi + #ij, 5 with x x D d x D x x D ( − x + 1−l (1−e )(e −e ) ) ¯ + (1−e )(e −e ) ¯ + 1−l (1−e )(e −e ) ¯ 1 e I−1 1−led−(1−l)ex xi 1−led−(1−l)ex lxj I−1 1−led−(1−l)ex ∑l6=i,j xl dij ≡ s w ew−eD e + e + I−1 1 − l (1 − ex)(ex − eD) 1 − l (1 − ex)(ex − eD) + (1 − ex + )(ln t ) + (ln t ) + k , − − d − ( − ) x ij − − d − ( − ) x ∑ lj j I 1 1 le 1 l e I 1 1 le 1 l e l6=i,j 1 − l (1 − ex)(ex − eD) 1 − l ew − eD dn ≡ (l − )( ln qn)/(es + ew + ) + (1 − eD)zn, − d x − ∑ l − I 1 1 − le − (1 − l)e I 1 l I 1 d x ( x − D)( l(1−e ) − 1−l (1−e ) )( − 1−l ) e e 1−led−(1−l)ex I−1 1−led−(1−l)ex l I−1 bM ≡ 1 + , s w ew−eD e + e + I−1 x 1−l (1 − e )(l − I−1 ) bX ≡ , s w ew−eD e + e + I−1 x x D d x D x x D ( − x + 1−l (1−e )(e −e ) )( n − ¯ ) + (1−e )(e −e ) ( n − ¯ ) + 1−l (1−e )(e −e ) ( n − ¯ ) 1 e I−1 1−led−(1−l)ex xi xi 1−led−(1−l)ex l xj xj I−1 1−led−(1−l)ex ∑l6=i,j xl xl #n ≡ ij s w ew−eD e + e + I−1 1 − l (1 − ex)(ex − eD) 1 − l (1 − ex)(ex − eD) + (ln tn − (ln t )) + (1 − ex + )(ln tn − (ln t )), − − d − ( − ) x ∑ lj lj − − d − ( − ) x ij ij I 1 1 le 1 l e l6=i,j I 1 1 le 1 l e 1 n where z¯ ≡ #diseases ∑n z denotes the arithmetic average of a given variable z across all diseases.
Load more

Recommended publications
  • Angiotensin-Converting Enzyme Inhibitors Or Angiotensin II Receptor Blockers and the Risk of Developing Rheumatoid Arthritis in Antihypertensive Drug Users
    Jong, H.J.I. de, Vandebriel, R.J., Saldi, S.R.F., Dijk, L. van, Loveren, H. van, Cohen Tervaert, J.W., Klungel, O.H. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiology and Drug Safety: 2012, 21(8), 835-843 Postprint Version 1.0 Journal website http://dx.doi.org/10.1002/pds.3291 Pubmed link http://www.ncbi.nlm.nih.gov/pubmed/22674737 DOI 10.1002/pds.3291 This is a NIVEL certified Post Print, more info at http://www.nivel.eu Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users†‡ HILDA J. I. DE JONG1,2,3, ROB J. VANDEBRIEL1, SITI R. F. SALDI3, LISET VAN DIJK4, HENK VAN LOVEREN1,2, JAN WILLEM COHEN TERVAERT5, OLAF H. KLUNGEL3,* ABSTRACT Purpose: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are effective in the treatment of cardiovascular disease. Next to effects on hypertension and cardiac function, these drugs have anti-inflammatory and immunomodulating properties which may either facilitate or protect against the development of autoimmunity, potentially resulting in autoimmune diseases. Therefore, we determined in the current study the association between ACE inhibitor and ARB use and incident rheumatoid arthritis (RA). Methods: A matched case–control study was conducted among patients treated with antihypertensive drugs using the Netherlands Information Network of General Practice (LINH) database in 2001–2006. Cases were patients with a first-time diagnosis of RA. Each case was matched to five controls for age, sex, and index date, which was selected 1 year before the first diagnosis of RA.
    [Show full text]
  • Adansonia Digitata L
    Veterinary World, EISSN: 2231-0916 RESEARCH ARTICLE Available at www.veterinaryworld.org/Vol.7/July-2014/10.pdf Open Access Antidiarrhoeal effect of the crude methanol extract of the dried fruit of Adansonia digitata L. (Malvaceae) Mohammed Musa Suleiman1111 , Mohammed Mamman , Ibrahim Hassan , Shamsu Garba , Mohammed Umaru Kawu21 and Patricia Ishaku Kobo 1. Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria; 2. Department of Physiology, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria. Corresponding author: Mohammed Musa Suleiman, email:[email protected] MM: [email protected], IH: [email protected], SG: [email protected], MUK: [email protected], PIK: [email protected] Received:06-04-2014, Revised: 12-06-2014, Accepted: 14-06-2014, Published online: 19-07-2014 doi: 10.14202/vetworld.2014.495-500 How to cite this article: Suleiman MM, Mamman M, Hassan I, Garba S, Kawu MUand Kobo PI (2014) Antidiarrhoeal effect of the crude methanol extract of the dried fruit ofAdansonia digitata L. (Malvaceae), Veterinary World 7(7): 495-500. Abstract Aim: The study was designed to evaluate the antidiarrhoeal property of the methanol extract of the fruit of Adansonia digitata using laboratory animal models. Materials and Methods : The acute oral toxicity (LD50 ) of the extract was determined in mice, while the antidiarrhoeal effect of different doses of the extract was evaluated in both mice and rats. The effect of the extract at doses of 300, 700 and 1000 mg/kg were tested against intestinal transit time, magnesium sulphate-induced gastrointestinal motility test and castor oil- induced diarrhoea in mice.
    [Show full text]
  • In Vivo Evaluation of Antidiarrhoeal Activity of the Leaves of Azima Tetracantha Linn
    Vol.5(8), pp. 140-144, December, 2013 DOI: 10.5897/IJNAM2013.0152 International Journal of Nutrition and ISSN 2141-2340 ©2013 Academic Journals http://www.academicjournals.org/IJNAM Metabolism Full Length Research Paper In vivo evaluation of antidiarrhoeal activity of the leaves of Azima tetracantha Linn V. Hazeena Begum*, M. Dhanalakshmi and P. Muthukumaran Department of Siddha Medicine, Faculty of Science, Tamil University, Vakaiyur, Thanjavur 613 010, Tamilnadu, India. Accepted 3 October, 2013 The aqueous crude extract of the leaves of Azima tetracantha was studied for its phytochemical constituents and antidiarrhoeal activity using castor oil-induced diarrhoea and castor oil-induced enteropooling in rats. The phytochemical studies of the aqueous extract revealed the presence of alkaloids, flavonoids, tannins and saponins. The extract showed significant (p < 0.001) protection against castor oil-induced diarrhoea and castor oil-induced enteropooling at (100 mg/kg). The presence of some of the phytochemicals in the root extract may be responsible for the observed effects, and also the basis for its use in traditional medicine as antidiarrhoeal drug. Key words: Azima tetracantha, enteropooling, anti-diarrhoeal. INTRODUCTION Diarrhoea is characterized by increased frequency of powerful diuretic given in rheumatism, dropsy, dyspepsia bowel movement, wet stool and abdominal pain and chronic diarrhoea and as a stimulant tonic after (Ezekwesili et al., 2004). It is a leading cause of confinement (Nadkarni, 1976). A. tetracantha as efficient malnutrition and death among children in the developing acute phase anti-inflammatory drug is traditionally used countries of the world today (Victoria et al., 2000). Many by Indian medical practitioners (Ismail et al., 1997).
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach
    www.nature.com/scientificreports OPEN Identifcation of candidate repurposable drugs to combat COVID‑19 using a signature‑based approach Sinead M. O’Donovan1,10, Ali Imami1,10, Hunter Eby1, Nicholas D. Henkel1, Justin Fortune Creeden1, Sophie Asah1, Xiaolu Zhang1, Xiaojun Wu1, Rawan Alnafsah1, R. Travis Taylor2, James Reigle3,4, Alexander Thorman6, Behrouz Shamsaei4, Jarek Meller4,5,6,7,8 & Robert E. McCullumsmith1,9* The COVID‑19 pandemic caused by the novel SARS‑CoV‑2 is more contagious than other coronaviruses and has higher rates of mortality than infuenza. Identifcation of efective therapeutics is a crucial tool to treat those infected with SARS‑CoV‑2 and limit the spread of this novel disease globally. We deployed a bioinformatics workfow to identify candidate drugs for the treatment of COVID‑19. Using an “omics” repository, the Library of Integrated Network‑Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID‑19 drugs and publicly available SARS‑CoV‑2 infected cell lines to identify novel therapeutics. We identifed a shortlist of 20 candidate drugs: 8 are already under trial for the treatment of COVID‑19, the remaining 12 have antiviral properties and 6 have antiviral efcacy against coronaviruses specifcally, in vitro. All candidate drugs are either FDA approved or are under investigation. Our candidate drug fndings are discordant with (i.e., reverse) SARS‑CoV‑2 transcriptome signatures generated in vitro, and a subset are also identifed in transcriptome signatures generated from COVID‑19 patient samples, like the MEK inhibitor selumetinib. Overall, our fndings provide additional support for drugs that are already being explored as therapeutic agents for the treatment of COVID‑19 and identify promising novel targets that are worthy of further investigation.
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacol Ther
    NIH Public Access Author Manuscript Pharmacol Ther. Author manuscript; available in PMC 2010 August 1. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacol Ther. 2009 August ; 123(2): 239±254. doi:10.1016/j.pharmthera.2009.04.002. Ethnobotany as a Pharmacological Research Tool and Recent Developments in CNS-active Natural Products from Ethnobotanical Sources Will C. McClatcheya,*, Gail B. Mahadyb, Bradley C. Bennettc, Laura Shielsa, and Valentina Savod a Department of Botany, University of Hawaìi at Manoa, Honolulu, HI 96822, U.S.A b Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL 60612, U.S.A c Department of Biological Sciences, Florida International University, Miami, FL 33199, U.S.A d Dipartimento di Biologia dì Roma Trè, Viale Marconi, 446, 00146, Rome, Italy Abstract The science of ethnobotany is reviewed in light of its multidisciplinary contributions to natural product research for the development of pharmaceuticals and pharmacological tools. Some of the issues reviewed involve ethical and cultural perspectives of healthcare and medicinal plants. While these are not usually part of the discussion of pharmacology, cultural concerns potentially provide both challenges and insight for field and laboratory researchers. Plant evolutionary issues are also considered as they relate to development of plant chemistry and accessing this through ethnobotanical methods. The discussion includes presentation of a range of CNS-active medicinal plants that have been recently examined in the field, laboratory and/or clinic. Each of these plants is used to illustrate one or more aspects about the valuable roles of ethnobotany in pharmacological research.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • Quality Use of Medicines in Residential Aged Care
    RESEARCH Quality use of medicines in Michael Somers residential aged care Ella Rose Dasha Simmonds Claire Whitelaw Janine Calver Christopher Beer Background Approximately 190 000 people in high risk of ADEs in frail older people. For example, Older people are more likely to be Australia were estimated to have anticholinergic drugs commonly produce adverse exposed to polypharmacy. People dementia in 2006, with the prevalence effects in elderly people and are more likely to be with dementia, especially those living expected to increase to 465 000 by 2031.1 prescribed to people with dementia than those in residential aged care facilities The prevalence of dementia increases without.7 (RACFs), are at particularly high risk of with age, from 6.5% of Australians aged Antipsychotic medications are commonly used medication harm. We sought to describe medications prescribed for a sample of 65 years and over to 22% of Australians to manage the behavioural and psychological 2 people with dementia living in RACFs. aged 85 years and over. Dementia is symptoms of dementia (BPSD), such as associated with a large burden of disease psychosis, depression, agitation, aggression Methods in Australia’s aging population, costing and disinhibition.1,8 There is concern that A total of 351 residents with dementia Australia $1.4 billion in 2003.2 Most of this antipsychotics are used too frequently as a aged over 65 years were recruited from 36 RACFs in Western Australia. burden was associated with residential first line treatment for BPSD, with the risks of 2 Data on all medications prescribed aged care facilities (RACFs). Dementia antipsychotic use outweighing the benefits at their were collected, including conventional is the medical problem most frequently likely level of use.8 For example, risperidone, an medications, herbal medications, managed by general practitioners atypical antipsychotic prescribed frequently for the vitamins and minerals.
    [Show full text]
  • Health and Social Outcomes Associated with High-Risk Alcohol Use
    Manitoba Centre for Health Policy Health and Social Outcomes Associated with High-Risk Alcohol Use Summer 2018 Nathan C Nickel, MPH, PhD Jeff Valdivia, MNRM, CAPM Deepa Singal, PhD James Bolton, MD Christine Leong, PharmD Susan Burchill, BMus Leonard MacWilliam, MSc, MNRM Geoffrey Konrad, MD Randy Walld, BSc, BComm (Hons) Okechukwu Ekuma, MSc Greg Finlayson, PhD Leanne Rajotte, BComm (Hons) Heather Prior, MSc Josh Nepon, MD Michael Paille, BHSc This report is produced and published by the Manitoba Centre for Health Policy (MCHP). It is also available in PDF format on our website at: http://mchp-appserv.cpe.umanitoba.ca/deliverablesList.html Information concerning this report or any other report produced by MCHP can be obtained by contacting: Manitoba Centre for Health Policy Rady Faculty of Health Sciences Max Rady College of Medicine, University of Manitoba 4th Floor, Room 408 727 McDermot Avenue Winnipeg, Manitoba, Canada R3E 3P5 Email: [email protected] Phone: (204) 789-3819 Fax: (204) 789-3910 How to cite this report: Nathan C Nickel, James Bolton, Leonard MacWilliam, Okechukwu Ekuma, Heather Prior, Jeff Valdivia, Christine Leong, Geoffrey Konrad, Greg Finlayson, Josh Nepon, Deepa Singal, Susan Burchill, Randy Walld, Leanne Rajotte, Michael Paille. Health and Social Outcomes Associated with High-Risk Alcohol Use. Winnipeg, MB. Manitoba Centre for Health Policy, Summer 2018. Legal Deposit: Manitoba Legislative Library National Library of Canada ISBN 978-1-896489-90-2 ©Manitoba Health This report may be reproduced, in whole or in part, provided the source is cited. 1st printing (Summer 2018) This report was prepared at the request of Manitoba Health, Seniors and Active Living (MHSAL), a department within the Government of Manitoba, as part of the contract between the University of Manitoba and MHSAL.
    [Show full text]
  • Anticoagulant Effects of Statins and Their Clinical Implications
    Review Article 1 Anticoagulant effects of statins and their clinical implications Anetta Undas1; Kathleen E. Brummel-Ziedins2; Kenneth G. Mann2 1Institute of Cardiology, Jagiellonian University School of Medicine, and John Paul II Hospital, Krakow, Poland; 2Department of Biochemistry, University of Vermont, Colchester, Vermont, USA Summary cleavage, factor V and factor XIII activation, as well as enhanced en- There is evidence indicating that statins (3-hydroxy-methylglutaryl dothelial thrombomodulin expression, resulting in increased protein C coenzyme A reductase inhibitors) may produce several cholesterol-inde- activation and factor Va inactivation. Observational studies and one ran- pendent antithrombotic effects. In this review, we provide an update on domized trial have shown reduced VTE risk in subjects receiving statins, the current understanding of the interactions between statins and blood although their findings still generate much controversy and suggest that coagulation and their potential relevance to the prevention of venous the most potent statin rosuvastatin exerts the largest effect. thromboembolism (VTE). Anticoagulant properties of statins reported in experimental and clinical studies involve decreased tissue factor ex- Keywords pression resulting in reduced thrombin generation and attenuation of Blood coagulation, statins, tissue factor, thrombin, venous throm- pro-coagulant reactions catalysed by thrombin, such as fibrinogen boembolism Correspondence to: Received: August 30, 2013 Anetta Undas, MD, PhD Accepted after major revision: October 15, 2013 Institute of Cardiology, Jagiellonian University School of Medicine Prepublished online: November 28, 2013 80 Pradnicka St., 31–202 Krakow, Poland doi:10.1160/TH13-08-0720 Tel.: +48 12 6143004, Fax: +48 12 4233900 Thromb Haemost 2014; 111: ■■■ E-mail: [email protected] Introduction Most of these additional statin-mediated actions reported are independent of blood cholesterol reduction.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • Deprescribing for Older Patients
    CMAJ Review CME Deprescribing for older patients Christopher Frank MD, Erica Weir MD MSc See related editorial at www.cmaj.ca/lookup/doi:10.1503/cmaj.122099 and articles at www.cmaj.ca/lookup/doi:10.1503/cmaj.122012 and www.cmaj.ca/lookup/doi:10.1503/cmaj.130523 he principles that guide optimal prescribing outcomes related to medications than other older Competing interests: None for older patients1,2 (Box 1) include depre- patients. They are also more likely to have limited declared. scribing medications that are no longer indi- life expectancy than well older people of similar This article has been peer T 17 cated, appropriate or aligned with evolving goals of age. Medication lists tend to lengthen as patients reviewed. care. Deprescribing is a relatively new term that age, and there are few guidelines to inform medi- Correspondence to: focuses attention on the sometimes overlooked step cation management in the context of polyphar- Christopher Frank, frankc in medication review of stopping medications to macy, multiple morbidities and age-related @providencecare.ca improve outcomes and decrease risks associated changes to pharmacokinetics and pharmacody- CMAJ 2014. DOI:10.1503 with polypharmacy in older people.3–5 These risks namics (Box 1). All prescribers contributing to the /cmaj.131873 include nonadherence,6 adverse drug reactions,7 medication list need to be alert to “prescribing functional and cognitive decline,8 and falls.9,10 In inertia”18 (the tendency to automatically renew a Canada, more than 50% of older people living in medication even when the original indication is long-term care facilities and 27% of those living in no longer present) and should view polypharmacy the community take more than five medications a as an impetus to deprescribe when appropriate.
    [Show full text]